


## Trend Report: Q3 2018


# Synthetic Cannabinoids in the United States

### New Synthetic Cannabinoids Identified Since January 2018


5F-MDMB-PICA




5Cl-AKB-48




4-cyano-CUMYL-BUTINACA



5F-EDMB-PINACA



### Positivity for Synthetic Cannabinoids Since January 2018



\*Plot based on date received. Testing of all samples submitted in August 2018 may not be complete.

## Purpose

The objective of this report is to provide up-to-date information regarding the status of synthetic cannabinoid prevalence, positivity, and discovery within the United States (March to August 2018).

## Project Overview

Novel psychoactive substances (NPS), including synthetic cannabinoids, continue to provide great challenges for forensic scientists, clinicians, and public health and safety personnel. Synthetic cannabinoids have been implicated in an increasing number of emergency room admissions, death investigations, and intoxication events in corrections populations. Maintaining a current scope of analysis can be challenging, often requiring availability of comprehensive analytical methodologies and reference materials for identifications.

This project employs a novel approach to analysis of biological samples and extracts by comprehensive non-targeted data acquisition using liquid chromatography high resolution quadrupole time-of-flight mass spectrometry (LC-QTOF). The scope of analysis contains more than 250 synthetic cannabinoid parent compounds and metabolites. Sample analysis and data processing occur on a weekly basis. In addition, retrospective analysis of datafiles is conducted as new synthetic cannabinoid standards become available. This model allows for real-time identification of novel synthetic cannabinoids and trend analyses.

Our laboratory has paired with various institutions to identify at-risk populations associated with synthetic cannabinoid use. Biological samples have been received from forensic laboratories, clinical partnerships, and/or correctional facilities from individuals involved in death investigations, driving under the influence scenarios, hospitalizations, and/or intoxications.

In collaboration with NMS Labs, sample extracts were received during this reporting period from forensic casework where for cause testing was directed for synthetic cannabinoids using a regularly updated panel. In total, cases were submitted from 24 states and the District of Columbia.

## Acknowledgements

This report was prepared by Alex J. Krotulski, MSFS; Amanda L.A. Mohr, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT at the Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation.

This project is supported by Award Number 2017-R2-CX-0021, awarded by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice. The opinions, findings, and conclusions or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect those of the Department of Justice.


## Disclaimer

All positive identifications were made based on extensive review of analytical data in comparison to acquired reference materials. Identifications of all chemically similar isobaric species may not have been achieved; therefore, reported analytes could encompass additional species not distinguishable solely by chromatographic or mass spectral features.

## New Synthetic Cannabinoids

From January to June 2018, four new synthetic cannabinoids have been identified in biological samples or sample extracts that were not incorporated into previous scope of testing and/or have not been reported in casework in the United States.

### 5F-MDMB-PICA



#### CHEMICAL INFORMATION

<b>IUPAC Name:</b>	Methyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate
<b>CFR:</b>	Not Scheduled (09/2018)
<b>CAS#:</b>	1971007-88-1
<b>Synonyms:</b>	5-Fluoro MDMB-PICA, 5F-MDMB-2201, MDMB-2201


#### SAMPLE INFORMATION

<b>Positive Cases:</b>	13
<b>First Collection:</b>	01/07/2018
<b>First Received:</b>	05/22/2018
<b>Locations:</b>	PA (n=5), NY (n=3), MD (n=2), IN (n=1), LA (n=1), TX (n=1)

#### REFERENCE

[5F-MDMB-PICA Monograph](#)

### 5Cl-AKB-48



#### CHEMICAL INFORMATION


<b>IUPAC Name:</b>	N-(1-adamantyl)-1-(5-chloropentyl)indazole-3-carboxamide
<b>CFR:</b>	Not Scheduled (09/2018)
<b>CAS#:</b>	Not available
<b>Synonyms:</b>	5-Chloro AKB48, 5Cl-APINACA, 5-Chloro APINACA

#### SAMPLE INFORMATION

<b>Positive Cases:</b>	1
<b>First Collection:</b>	07/11/2018
<b>First Received:</b>	07/09/2018
<b>Locations:</b>	PA (n=1)

#### REFERENCE

[5Cl-AKB-48 Monograph](#)

**4-cyano-CUMYL-BUTINACA****CHEMICAL INFORMATION**


<b>IUPAC Name:</b>	1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)indazole-3-carboxamide
<b>CFR:</b>	Schedule 1
<b>CAS#:</b>	1631074-54-8
<b>Synonyms:</b>	4-CN-CUMYL-BUTINACA, CUMYL-4CN-BINACA, CUMYL-CB-PINACA, CUMYL-CYBINACA, SGT-78

**SAMPLE INFORMATION**

<b>Positive Cases:</b>	4
<b>First Collection:</b>	05/23/2018
<b>First Received:</b>	07/30/2018
<b>Locations:</b>	PA (n=2), IL (n=2)

**REFERENCE**

- [Bovens et al. \(2017\) Structural characterization of the new synthetic...](#)  
[Kuehn \(2018\) Synthetic Cannabidiol Poisoning.](#)  
[Åstrand et al. \(2018\) Metabolism study for CUMYL-4CN-BINACA...](#)

**5F-EDMB-PINACA****CHEMICAL INFORMATION**

<b>IUPAC Name:</b>	Ethyl 2-[[1-(5-fluoropentyl)indazole-3-carbonyl]amino]-3,3-dimethyl-butanoate
<b>CFR:</b>	Not Scheduled (09/2018)
<b>CAS#:</b>	Not available
<b>Synonyms:</b>	5-Fluoro EDMB-PINACA

**SAMPLE INFORMATION**

<b>Positive Cases:</b>	4
<b>First Collection:</b>	06/03/2018
<b>First Received:</b>	06/01/2018
<b>Locations:</b>	TX (n=3), NY (n=1)

**REFERENCE**

- [Liu et al. \(2018\) Identification and analytical characterization of six...](#)

## Trend Analysis for Synthetic Cannabinoids

From January through August 2018, 17 synthetic cannabinoids were positively identified in 179 (17.3%) biological samples or sample extracts after the analysis of 1,037 total specimens. 5F-ADB (or 5F-MDMB-PINACA, n=100) was detected in the highest frequency, followed by MMB-FUBINACA (or FUB-AMB, n=25), ADB-FUBINACA (n=13), and 5F-MDMB-PICA (n=13). Several samples were positive for more than one synthetic cannabinoid, including parent compounds and/or metabolites. These results are consistent with the national trend data reported by the National Forensic Laboratory Information System (NFLIS).

**Table 1: Positive Findings for Synthetic Cannabinoids (Parent)**


Analyte (Parent)	Positive Samples	Positivity (%)
5F-ADB	100	9.6
MMB-FUBINACA	25	2.4
ADB-FUBINACA	13	1.3
5F-MDMB-PICA	13	1.3
4-cyano CUMYL-BUTINACA	4	0.4
5F-EDMB-PINACA	4	0.4
FUB-AKB-48	4	0.4
5F-ADBICA	2	0.2
AB-PINACA	2	0.2
AB-CHMINACA	2	0.2
5F-AMB	1	0.1
5F-ADB-PINACA	1	0.1
5F-PB-22	1	0.1
MMB-CHMICA	1	0.1
MDMB-FUBINACA	1	0.1
5CI-AKB-48	1	0.1
MAB-CHMINACA	1	0.1

**Table 2: Positive Findings for Synthetic Cannabinoids (Metabolites)**


Analyte (Metabolite)	Positive Samples	Positivity (%)
5F-ADB 3,3-Dimethylbutanoic Acid	61	5.9
MMB-FUBINACA 3-Methylbutanoic Acid	48	4.6
4-cyano CUMYL-BUTINACA N-Butanoic Acid	2	0.2

**Table 3: Synthetic Cannabinoid Combinations**


Analyte Combinations	Positive Samples
5F-ADB + MMB-FUBINACA	4
MMB-FUBINACA + 5F-MDMB-PICA	3
5F-ADB + 5F-EDMB-PINACA	3
MMB-FUBINACA + FUB-AKB-48	3
5F-ADB + 5F-MDMB-PICA	2
5F-ADB + MMB-FUBINACA+ 5F-MDMB-PICA	1




**Figure 1: Synthetic Cannabinoids Positivity Trend Plot**




**Figure 2: Age (n=179)**



**Figure 3: Gender (n=179)**



**Figure 4: Case Type (n=179)**



**Figure 5: Other Notable Positive Findings**

**Glossary of Synonyms**

Reported Name	Synonym(s)
5F-ADB	5F-MDMB-PINACA
MMB-FUBINACA	FUB-AMB, AMB-FUBINACA
4-cyano CUMYL-BUTINACA	CUMYL-4CN-BINACA, CUMYL-CB-PINACA, CUMYL-CYBINACA, SGT-78
FUB-AKB-48	AKB48 N-(4-Fluorobenzyl) Analogue, AFB-48, AFUBINACA, FUB-APINACA
5F-AMB	5F-AMP, 5F-MMB-PINACA
5F-PB-22	5F-QUPIC
MMB-CHMICA	AMB-CHMICA
MDMB-FUBINACA	FUB-MDMB, MDMB-Bz-F